BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20187324)

  • 1. Development of PARP inhibitors: an unfinished story.
    Patel A; Kaufmann SH
    Oncology (Williston Park); 2010 Jan; 24(1):66, 68. PubMed ID: 20187324
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
    Stebbing J; Ellis P; Tutt A
    Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
    [No Abstract]   [Full Text] [Related]  

  • 3. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 4. An Achilles' heel for breast cancer?
    Caldecott KW; Chalmers A
    Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
    [No Abstract]   [Full Text] [Related]  

  • 5. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 6. PARP inhibitors: what we know and what we have yet to know.
    Puhalla S
    Oncology (Williston Park); 2010 Jan; 24(1):62, 65-6. PubMed ID: 20187323
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
    Bouwman P; Jonkers J
    Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of oncogenetics in the treatment of breast and ovarian cancer].
    Langmár Z; Németh M
    Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
    [No Abstract]   [Full Text] [Related]  

  • 11. PARP inhibition as a prototype for synthetic lethal screens.
    Liu X
    Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibition and synthetic lethality in ovarian cancer.
    Eskander RN; Tewari KS
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):613-22. PubMed ID: 24984781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibition in breast cancer.
    Garber J
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
    [No Abstract]   [Full Text] [Related]  

  • 14. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer: crossing over to drug resistance.
    Livingston DM; Silver DP
    Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
    [No Abstract]   [Full Text] [Related]  

  • 18. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
    Mercier-Vogel L; Bodmer A; Castiglione M
    Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
    Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
    J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
    [No Abstract]   [Full Text] [Related]  

  • 20. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.